摘要
目的:研究缬沙坦联合阿法骨化醇治疗糖尿病肾病的临床疗效。方法:选取2015至2017年,100例住院接受糖尿病肾病治疗的患者,随机将其分为2组,每组50名,分别随机分为观察组与对照组。观察组采用单用缬沙坦胶囊(80mg/d),对照组联合缬沙坦胶囊(80mg/d)和阿法骨化醇(0.5μg/d)治疗,应将血压均值控制在130/80mmHg以下,8周为1个疗程,在治疗的初期与末期,对2组患者的血压、尿微量白蛋白排泄率(UAER)的变化等指标,进行有效监测,在其检测的过程中,针对治疗期间是否发生不良反应进行有效地观察。结果:对所选取的100例糖尿病肾病患者在接受治疗的过程中,无不良反应。差异无统计学意义(P>0.05)。结论:缬沙坦、阿法骨化醇在治疗糖尿病肾病上,能有效地降低患者的蛋白尿,保护肾脏。
Purpose: To study the clinical effect of Valsartan and Alfacalcidol Tablets in the treatment of diabetic nephropathy. Method: In 2015-2017, 100 patients were hospitalized for treatment of diabetic nephropathy, randomly divided it into 2 groups, observation group and control group, with 50 in each group. The observation group used valsartan tablets, and the control group patients were treated with combined valsartan tablets and Alfacalcidol Tablets. The mean blood pressure should be kept below 130/80 mmHg.8 weeks for 1 course. In the early and late stages of treatment, the changes in blood pressure and urinary microalbumin excretion rate(UAER)were effectively monitored in two groups of patients. In the process of its detection, it is effective to observe whether adverse reactions occur during treatment. Results: There were no adverse reactions in the treatment of 100 patients with diabetic nephropathy. The difference is not statistically significant( P >0.05). Conclusion: Valsartan and Alfacalcidol Tablets can effectively reduce the proteinuria of patients and protect the kidneys in the treatment of diabetic nephropathy.
作者
徐璐璐
XU Lu-lu(Department of Endocrinology, First Affiliated Hospital of Henan University, Kaifeng Henan 475000, China)
出处
《药品评价》
CAS
2019年第3期15-16,50,共3页
Drug Evaluation
基金
河南省医学科技攻关计划项目(18B310011)
关键词
缬沙坦
阿法骨化醇
糖尿病肾病
Valsartan
Alfacalcidol Tablets
Diabetes Nephropathy
